You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

53 Results
Document
May 2019
Guidelines and Advice
Status: Archived
ID: 2-14
Version: 3
Apr 2011
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Symptom Management
Symptom Management
The New Drug Funding Program (NDFP) and pays for many newer, and often very expensive, injectable cancer drugs administered in hospitals and cancer...
Cancer facts
Sep 2015
Guidelines and Advice
Status: Current
ID: GL 4-1
Version: 2
Jan 2021
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PERTuzumab,
trastuzumab,
nab-PACLitaxel (Unfunded with exceptions)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023

Pages